148 related articles for article (PubMed ID: 12615426)
1. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
Dela Cruz JS; Lau SY; Ramirez EM; De Giovanni C; Forni G; Morrison SL; Penichet ML
Vaccine; 2003 Mar; 21(13-14):1317-26. PubMed ID: 12615426
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
3. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
Dela Cruz JS; Morrison SL; Penichet ML
Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
[TBL] [Abstract][Full Text] [Related]
4. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
5. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
Pakravan N; Hashemi SM; Hassan ZM
Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
[TBL] [Abstract][Full Text] [Related]
7. The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.
Dimitriadis A; Gontinou C; Baxevanis CN; Mamalaki A
BMC Cancer; 2009 Oct; 9():386. PubMed ID: 19878568
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
9. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
Helguera G; Rodríguez JA; Penichet ML
Mol Cancer Ther; 2006 Apr; 5(4):1029-40. PubMed ID: 16648575
[TBL] [Abstract][Full Text] [Related]
10. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
11. CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
Nguyen-Hoai T; Baldenhofer G; Ahmed MS; Pham-Duc M; Gries M; Lipp M; Dörken B; Pezzutto A; Westermann J
J Gene Med; 2012 Feb; 14(2):128-37. PubMed ID: 22228591
[TBL] [Abstract][Full Text] [Related]
12. Immunization with HER2 extracellular subdomain proteins induces cellular response and tumor growth inhibition in mice.
Ahmadi M; Sadri-Ardalani F; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
Immunotherapy; 2018 Mar; 10(6):511-524. PubMed ID: 29562854
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.
Bhattachary R; Bukkapatnam R; Prawoko I; Soto J; Morgan M; Salup RR
Int Immunopharmacol; 2002 May; 2(6):783-96. PubMed ID: 12095169
[TBL] [Abstract][Full Text] [Related]
14. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
[TBL] [Abstract][Full Text] [Related]
15. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
17. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
Penichet ML; Dela Cruz JS; Shin SU; Morrison SL
Hum Antibodies; 2001; 10(1):43-9. PubMed ID: 11455061
[TBL] [Abstract][Full Text] [Related]
18. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
19. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
[TBL] [Abstract][Full Text] [Related]
20. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
Fuenmayor J; Perez-Vazquez K; Perez-Witzke D; Penichet ML; Montano RF
Mol Cancer Ther; 2010 Aug; 9(8):2175-85. PubMed ID: 20682652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
